DFTX Definium Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DFTX matters now
Definium Therapeutics, Inc. (DFTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $47.07 with -2.85% on the session and $5.13B in market capitalization; recent performance reads 1-month +22.28% and YTD +82.82%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-77.1M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.4%.
The latest indexable market news headline is "Definium Therapeutics Announces New Employee Inducement Grants" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $36.50; recent insider activity includes Bruhn Suzanne Louise filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
9.55
P/S
0.00
EV/EBITDA
-10.83
DCF Value
$2.83
FCF Yield
-5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.5%
ROA
-59.2%
ROIC
-60.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-77.1M | $-0.71 |
| Q4 2025 | $0.00 | $-50.4M | $-0.50 |
| FY 2025 | $0.00 | $-183.8M | $-2.06 |
| Q3 2025 | $0.00 | $-67.3M | $-0.78 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.50
Target (Median)
$36.50
Target Range
$25.00 - $48.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.38
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.